Canaccord analyst William Plovanic raised the firm’s price target on Staar Surgical (STAA) to $30.75 from $28 and keeps a Hold rating on the shares. The firm noted Alcon (ALC) announced this morning an amended merger agreement with Staar Surgical, where the they have increased its acquisition price to $30.75 from previous $28, a 10% increase in its bid.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Broadwood continues to urge Staar shareholders to vote against Alcon transaction
- Midday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat
- Alcon amends merger agreement with Staar Surgical, increases acquisition price
- Staar Surgical Amends Merger Agreement with Alcon
- Broadwood Partners reiterates opposition to Staar Surgical’s sale to Alcon